Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vemurafenib
Drug ID BADD_D02344
Description Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E.[A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF.[A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. [L1012]
Indications and Usage Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation.[L1013] Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.[A31272]
Marketing Status Prescription
ATC Code L01EC01
DrugBank ID DB08881
KEGG ID D09996
MeSH ID D000077484
PubChem ID 42611257
TTD Drug ID D0Y9EW
NDC Product Code 50242-090
Synonyms Vemurafenib | PLX4032 | PLX 4032 | RG7204 | RG-7204 | RG 7204 | Zelboraf | R05185426
Chemical Information
Molecular Formula C23H18ClF2N3O3S
CAS Registry Number 918504-65-1
SMILES CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cutaneous sarcoidosis23.03.15.004; 10.02.06.0020.000650%Not Available
Cyst16.02.02.002; 08.03.05.0010.001732%Not Available
Cystitis20.03.02.002; 11.01.14.0010.000650%
Death08.04.01.0010.017456%
Decreased activity19.11.01.002; 08.01.01.0060.007796%Not Available
Dehydration14.05.05.0010.007363%
Depressed level of consciousness17.02.04.002--
Depression19.15.01.001--
Dermal cyst23.10.02.001; 16.26.02.0010.001732%Not Available
Dermatitis23.03.04.0020.004114%Not Available
Dermatitis acneiform23.02.01.0040.005197%
Dermatitis allergic23.03.04.003; 10.01.03.0140.000650%Not Available
Dermatitis bullous23.03.01.0020.001732%
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.003248%
Dermatitis infected23.03.04.024; 11.01.12.0110.000433%Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.000433%Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Disorientation17.02.05.015; 19.13.01.002--Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000226%
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.003032%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry mouth07.06.01.002--
Dry skin23.03.03.0010.006713%
Duodenal ulcer07.04.02.0020.000433%
Dupuytren's contracture15.03.03.0030.001299%Not Available
Dysaesthesia17.02.06.0030.000433%
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia17.02.07.003; 07.14.03.0010.007796%
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 19 Pages